NCT04128501 2026-03-06
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
20 trialsNCT07159620 2025-09-08
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07081607 2025-07-23
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07012447 2025-06-10
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06686108 2025-05-07
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT06778902 2025-01-16
Dragon
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT05958719 2024-12-30
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05376111 2024-12-27
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT03542266 2023-08-22
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
Phase 2 Completed
NCT01241786 2022-07-20
VZCLLPI0146
Hackensack Meridian Health
Phase 2 Terminated
NCT05008666 2021-08-17
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT04052659 2021-03-09
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking University
Phase 2 Unknown
NCT02458235 2020-10-12
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
Phase 2 Completed
NCT03719989 2018-10-25
EPIC
Seoul National University Hospital
Phase 2 Unknown
NCT01121757 2016-09-12
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Phase 2 Terminated
NCT00543582 2015-07-01
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00413478 2015-06-30
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed